论文部分内容阅读
胚胎肝脏造血干细胞可代替骨髓造血干细胞治疗多种免疫和造血系统疾病。胎肝移植有不发生移植物抗宿主病(GVHD)的优点,在我国还具有胎肝来源充足的特点。限制胎肝移植在临床应用的主要原因是胎肝造血干细胞在受体内不能长期存活,关键是难于克服受体的排斥反应。我们用BALB/C
Embryonic liver hematopoietic stem cells can replace bone marrow hematopoietic stem cells to treat a variety of immune and hematopoietic system disorders. Fetal liver transplantation does not occur with the advantages of graft-versus-host disease (GVHD), in our country also has a sufficient source of fetal liver characteristics. The main reason that restricts fetal liver transplantation in clinical application is that fetal liver hematopoietic stem cells can not survive for a long time in the recipient, and the key point is that it is difficult to overcome the rejection of the recipient. We use BALB / C